Literature DB >> 20803510

Dysplastic lesions in ulcerative colitis: changing paradigms.

Patrick B Allen1, Michael A Kamm, Peter De Cruz, Paul V Desmond.   

Abstract

Crohn and Rosenberg first highlighted the increased risk of colorectal cancer in ulcerative colitis in 1925. Cancer rates as high as 34 percent after 30 yrs of disease have been reported in several population-based studies, although the reported risk varies substantially. Lower rates have been reported in: population-versus specialist centre-cohorts, local practices with a high colectomy rate and high 5-aminosalicylate usage, and more recent as opposed to older reports. Despite this variation in reported risk, and lack of controlled evidence for cancer reduction, colonoscopic surveillance programmes are a routine part of care in many centres. Cancer is believed to arise most commonly in dysplastic epithelium, and the detection of either dysplasia or early cancer forms the basis of such programmes. Further confusion stems from the variety of terms used to describe dysplastic change.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20803510     DOI: 10.1002/ibd.21227

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  3 in total

Review 1.  Colon Cancer: Inflammation-Associated Cancer.

Authors:  Sherief Shawki; Jean Ashburn; Steven A Signs; Emina Huang
Journal:  Surg Oncol Clin N Am       Date:  2017-12-15       Impact factor: 3.495

2.  Low Prevalence of Colon Polyps in Chronic Inflammatory Conditions of the Colon.

Authors:  Amnon Sonnenberg; Robert M Genta
Journal:  Am J Gastroenterol       Date:  2015-04-28       Impact factor: 10.864

3.  Consensus on the Prevention, Screening, Early Diagnosis and Treatment of Colorectal Tumors in China: Chinese Society of Gastroenterology, October 14-15, 2011, Shanghai, China.

Authors:  Jing-Yuan Fang; Shu Zheng; Bo Jiang; Mao-De Lai; Dian-Chun Fang; Ying Han; Qian-Jiu Sheng; Jing-Nan Li; Ying-Xuan Chen; Qin-Yan Gao
Journal:  Gastrointest Tumors       Date:  2014-05-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.